Prof Heather Wakelee speaks to ecancer about the IMpower010 trial.
This study investigated atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC.
Initially, Dr Wakelee explains the rationale of the study. She then discusses the methodology and results of this study.
Dr Wakelee mentions that IMpower010 met its primary endpoint, showing DFS benefit with adjuvant atezo vs BSC after adjuvant chemo in patients with resected Stage II-IIIA NSCLC, with pronounced benefit in the PD-L1 TC ≥1% subgroup.
The safety profile of atezo was consistent with prior experience of atezo monotherapy across indications and lines of therapy.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.